Topical Product Performance Testing Patents: Leaders & Trends 2026
- 41.5% concentration. The top 5 assignees hold 460 of the 1,109 records in scope — a field where a handful of filers set the terms for release-rate and membrane-selection claims.
- Filing has not slowed. 2021 to 2024 filings grew 6% (52 to 55), the last span the data can call complete once the 18-month publication lag is accounted for.
- A61K dominates, A61N barely registers. 91.5% of records touch medicinal preparations (A61K) while electrotherapy/radiation delivery (A61N) sits at just 1.6% — a visible gap next to a crowded core.
Filing growth compares 2021 (52 records) with 2024 (55) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,109 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Topical product performance testing sits at the intersection of formulation science and regulatory method — in vitro permeation testing, topical bioequivalence, and the release-rate and membrane-selection protocols that regulators use to judge whether a generic or reformulated topical product behaves like its reference. The 1,109 records in scope span 2015 through mid-2026 and cover filings built around sampling protocol, statistical criteria, regulatory guidance and batch variability — the mechanics of proving a topical product performs consistently, not just that it contains an active ingredient.
Because a single filing can claim both a delivery system and a testing method, the technology composition below is read by class share of the full record set, not as parts of a whole. Publication lag means the most recent one to two filing years will always look thinner than they will once the full record set catches up.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 1,109 records: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Filings ran from 82 in 2017 to a peak of 89 in 2018, then held in a comparable band through the mid-2020s; the 2021-2024 span shows 6% growth (52 to 55). 2025 and 2026 figures are still filling in behind the publication lag and should not be read as a decline.
IPC subclass composition
A61K (medicinal preparations) touches 91.5% of records, reflecting how tightly performance-testing claims are tied to formulation. A61P (therapeutic activity) follows at 34.7%. Device- and material-adjacent classes — A61M, A61F, A61L, C07C, A23L, A61N — each sit under 9%, marking areas where claim density is comparatively light.
Shares are the percentage of the 1,109 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Topical Product Performance Testing with Eureka
This page is one run against one query. Ask Eureka your own question about topical product performance testing and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
EP0519926B1 — Transdermal system with inclusion-complex release control
The filing concerns a transdermal system with a reservoir layer comprising an active substance, at least part of which forms an inclusion complex with a cyclo compound. The release rate from the system is controlled by the dissociation of that complex rather than by a physical rate-limiting membrane alone.Filed by Pharmacia AB; granted 1996-05-01.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US4568343A | Skin permeation enhancer compositions | 659 |
| 2 | US4060084A | Method and therapeutic system for providing chemotherapy transdermally | 447 |
| 3 | US5770219A | Solid matrix system for transdermal drug delivery | 349 |
| 4 | US4915950A | Printed transdermal drug delivery device | 267 |
| 5 | US20060045865A1 | Controlled regional oral delivery | 266 |
| 6 | US4746515A | Skin permeation enhancer compositions using glycerol monolaurate | 258 |
| 7 | US5310559A | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporati… | 222 |
| 8 | US5252334A | Solid matrix system for transdermal drug delivery | 174 |
| 9 | US6149935A | Solid matrix system for transdermal drug delivery | 164 |
| 10 | US4951657A | Heat sealable membrane for transdermal drug release | 154 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside the searched corpus; treat them as a signal of influence on the field's foundational methods, not as a ranking of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three read-outs from the numbers above, framed around where a new filer or licensor should focus attention.
The core is occupied, not evenly
Just five assignees hold 460 of the 1,109 records in scope. That is not a monopoly on the field, but it means the foundational release-rate and membrane-selection claims are already staked out; new filers should expect to design around, not simply file alongside, this cluster.
Steady, not surging
The only span of the trend that can be called complete — 2021 through 2024 — shows modest, sustained growth rather than a spike. Given the roughly 18-month lag between filing and publication, the apparent tail-off after 2024 is an artefact of the data cut-off, not a real slowdown.
Device-adjacent classes are thin
A61K dominates at 91.5% of records, but device- and energy-delivery-adjacent classes — A61M, A61F, A61L, A61N — each sit in single digits. That gap sits next to a crowded formulation core and is worth checking before assuming it is unclaimed for a reason.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to topical product performance testing, with the prior art for and against each one.
Who is filing, and where the field is open
The ranking covers 100 companies returned by the data endpoint — not a top-50 or top-100 cut, the full ranked list the dataset provides. A small number of names dominate the top of it; most of the remaining ranked entrants file in single digits.
One filer sets the pace
The leading assignee's record count outstrips fifth place (36) by a wide margin, suggesting a filer that treats topical performance-testing method claims as core IP rather than a peripheral filing category.
Recent-year activity is thin across the board
Even among named assignees with recent-year filings, counts are small — two records at most in the latest year — and several leading historical filers show zero recent-year activity. That is consistent with publication lag rather than abandonment of the space.
A tight collaboration core
Ten co-assignee pairs appear in the dataset, with the strongest pairing filing together far more often than any other combination — a sign of a formal supply or development relationship rather than incidental co-inventorship.
| Assignee | Recent year | YoY |
|---|---|---|
| Aquestive Therapeutics Inc | 2 | — |
| Incyte Corp | 1 | -67% |
| LTS Lohmann Therapie-Systeme AG | 0 | — |
| Alza Corp | 0 | — |
| Principia Biopharma Inc | 0 | — |
| Taris Biomedical | 0 | -100% |
| Dow Silicones Corp | 0 | — |
| Pharmacia AB | 0 | — |
Where to take this next
The numbers point to a concentrated core and a thin periphery. Turning that into a filing or licensing decision means going claim by claim.
Map the leader's claim boundaries
Before filing near release-rate or membrane-selection methods, chart exactly what the top-ranked assignee's granted claims cover versus what remains open around them.
Explore claim charts in EurekaTest the under-claimed branches
A61N and A61L-adjacent filings are thin relative to A61K. Confirm whether that reflects real technical difficulty or simply unclaimed space before committing R&D.
Run a white-space search in EurekaWatch the co-filing core
The strongest co-assignee pair files together far more than any other combination in this dataset — worth tracking for supply or licensing signals.
Track assignee activity in EurekaCommon questions on this landscape
In this dataset it means filings whose claims combine a topical delivery mechanism (transdermal patch, reservoir, matrix system) with a method for testing or demonstrating its performance — in vitro permeation testing, topical bioequivalence, release-rate measurement, membrane selection, or the sampling and statistical protocols regulators use to judge batch variability. It is a narrower category than dermatology or transdermal delivery generally: it is specifically about proving that a product performs as intended, not just formulating it. That framing is why A61K (medicinal preparations) appears in over 91% of records — the testing method claims are usually attached to a formulation claim.
The dataset ranks 100 assignees by record count, with a clear leader holding 255 records against 36 at fifth place and 18 at tenth — a steep drop-off rather than a gradual one. The top 5 combined account for 41.5% of all 1,109 records in scope, and the top 10 for 51.6%. Beyond the ranked leaders, filing activity spreads into a long tail of companies with single-digit record counts, typical of a field with a dominant core and many peripheral entrants.
Over the only span that can currently be treated as complete, 2021 to 2024, filings grew 6%, from 52 to 55 records. Filing counts for 2025 and 2026 appear lower in the raw data, but that reflects the roughly 18-month lag between when a patent is filed and when it publishes, not an actual drop in activity. The field's peak filing year to date was 2018, at 89 records, and volumes since have settled into a steadier band rather than a sharp decline.
Relative to the dominant A61K formulation class (91.5% of records) and A61P therapeutic-activity class (34.7%), device- and energy-adjacent classes are thin: A61M (body-fluid devices) at 8.8%, A61F (implants) at 7.6%, A61L (sterilisation) at 4.1%, and A61N (electrotherapy/radiation) at just 1.6%. These lighter classes sit next to a crowded core, which makes them worth investigating first for open claim space, though a first filer should confirm whether the low density reflects a real technical barrier before assuming it is simply unclaimed.
EP0519926B1 claims a transdermal system in which the active substance's release rate is controlled by the dissociation of an inclusion complex formed between the active substance and a cyclo compound, rather than by a conventional rate-limiting membrane. It is a specific mechanism, not a claim over transdermal delivery or performance testing broadly, so it constrains designs that rely on complex-dissociation-based release control but leaves membrane-based, matrix-based and other release mechanisms open. Anyone designing a system with inclusion-complex release kinetics should review its claim scope closely before proceeding.
Research Topical Product Performance Testing in depth with Eureka
Go past this page: query the whole topical product performance testing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.